Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus low-dose dexamethasone for prevention of new-onset atrial fibrillation after CABG
PACTR202610535995390Phase 1Completed
- Sponsor
- Kafrelsheikh University Hospital
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of empagliflozin and dexamethasone in Atrial fibrillation (AFib) (2 arms), sponsored by Kafrelsheikh University Hospital. Primary endpoint: Incidence of new-onset atrial fibrillation within 72 hours postoperatively. Started Mar 2026; status: completed.
02
Drugs
empagliflozindexamethasone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on PACTR202610535995390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610535995390.